The US healthcare system continues to burden patients with complexity, fragmentation, and out-of-pocket costs they weren't prepared to shoulder.

At BIO 2025 in Boston today, pharma and biotech leaders discussed the current state of AI in the drug development life cycle.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Discover the essential factors required to successfully scale GenAI in the pharmaceutical industry, from pilot programmes to impactful implementation. Gain insights on the challenges and ...

The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.

At the second annual HLTH Europe event in Amsterdam, Deep Dive editor Eloise McLennan sat down with ABIG Health founder and ...

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

From robot-assisted surgery to personalised disease treatment - technology can do some truly remarkable things. But while the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...